RxDoctor Payments DataLook up a doctor →

Harry Studdard, MD

Internal Medicine · Mobile, ALNPI 1144217837

Payments from drug & device makers

$12,883,054in general payments, 2019–2025

Across 2,966 payments — averaging $4343.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$4.4M
  • Emergent Biosolutions Inc.$2.2M
  • Johnson & Johnson$1.5M
  • Seqirus USA Inc$1.3M
  • Novavax Inc$542K
  • GSK$528K
  • plus $2.5M from 54 others
$26,791in research payments, 2019–2025

Across 3 payments — averaging $8930.34 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$27K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer333$4,378,459
Emergent Biosolutions Inc.1,188$2,177,352
Johnson & Johnson34$1,461,440
Seqirus USA Inc619$1,290,505
Novavax Inc11$541,792
GSK74$527,969
Eli Lilly13$363,964
Amgen8$327,157
Sanofi Pasteur Inc.19$319,666
Bavarian Nordic A/s27$282,701
Boehringer Ingelheim40$258,922
Astrazeneca UK Limited4$213,011
Janssen Research & Development, LLC14$200,343
Viiv Healthcare Company7$185,212
Takeda Pharmaceuticals U.S.A., Inc.11$158,727
Biohaven Pharmaceuticals, Inc.17$56,708
Currax Pharmaceuticals LLC25$49,075
Biohaven Pharmaceutical Holding Company Ltd.10$21,410
Boehringer Ingelheim International GmbH104$20,242
AstraZeneca41$17,521
Merck3$15,022
Dr.reddy's Laboratories,inc.1$6,235
Swedish Orphan Biovitrum AB3$3,471
AbbVie(2 entities)60$799
Novo Nordisk50$755
Bayer40$666
Corcept Therapeutics20$460
Amarin Pharma, Inc.24$367
Organogenesis Inc.16$341
Lilly USA, LLC20$337
Vanda Pharmaceuticals Inc.10$259
Dexcom, Inc.16$221
Esperion Therapeutics, Inc.10$147
Astellas Pharma US Inc3$130
Xeris Pharmaceuticals, Inc.6$118
Paratek Pharmaceuticals, Inc.6$117
Novartis6$92
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC5$92
Bioventus LLC3$88
KCI USA, Inc.4$85
Exact Sciences5$84
Kowa Pharmaceuticals America, Inc.6$80
Bsn Medical Inc3$75
Azurity Pharmaceuticals, Inc.5$72
Smith+Nephew4$67
Otsuka America Pharmaceutical, Inc.3$65
Abbott3$62
Mannkind Corporation4$58
Shield Therapeutics Inc3$46
Convatec Inc.2$44
Solventum Corporation2$43
BETA Bionics, Inc.2$42
Melinta Therapeutics, LLC2$41
Eisai Inc.2$38
Integra Lifesciences Corporation1$33
Antares Pharma, Inc.2$32
Optinose US, Inc.2$28
Insulet Corporation1$22
Nestle Healthcare Nutrition Inc.1$20
Boston Scientific1$19

How this compares

$12,883,054 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.

See all internal medicine providers in Alabama →

Medicare billing

Part B allowed, 2024
$65,012
Medicare patients
150
Services billed
835

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Mobile

See the full list for Alabama →

Where these figures come from

Is this you, or does something look wrong? →